Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
Nuclear Medicine
MIBG 131 WITHOUT CARRIER (R&D)
Name:
MIBG 131 without carrier (R&D)
Active Principle:
Iobenguan 131I
Therapeutic Action:
It is a radioactive therapeutic agent indicated for the treatment of adult and pediatric patients 12 years of age and older with iobenguane-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic antineoplastic therapy.
RELATED PRODUCTS
-
AV45 (R+D)
AV45 (R+D)It is indicated for estimating the density of β-amyloid neuritic plaque in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive... -
PARTITION FLASK
PARTITION FLASKVial containing a mixture of solvents to carry out a chromatographic separation ... -
177Lu DOTATATE (I+D)
177Lu DOTATATE (I+D)It is a radiolabeled somatostatin analog indicated for: - The treatment of gastroenteropancreatic tumors positive for the somatostatin receptor. Neuroendocrine tumors (GEP-NETs), including the foregut... -
FLPET (R+D)
FLPET (R+D)It is indicated for the detection and evaluation of cell proliferation in lung, breast, colorectal, melanoma, soft tissue sarcoma and primary or metastatic brain tumors. It allows to predict the aggressiveness...

